| Guo, Ying |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
| Recruiting | N/A | 1000 | RoW | | Huashan Hospital, LanZhou University, Xingtai People's Hospital, The Third Central Hospital of Tianjin, The Third People's Hospital of Taiyuan, Lishui Country People's Hospital, Baoding People's Hospital, The Affiliated Hospital of Qingdao University, Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, The Fifth People's Hospital of Wuxi, Jincheng People's Hospital, The Sixth Peoples Hospital of Shenyang, Zhenjiang Third Hospital, The Third People's Hospital of Linfen City, The First Affiliated Hospital of Dalian Medical University, The Fourth People's Hospital of Qinghai Province, The Third People's Hospital of Tibet Autonomous Region, The Second Affiliated Hospital of Chongqing Medical University, Peking University Health Science Center, The Affiliated Hospital Of Southwest Medical University | COVID-19, Vaccine Reaction, Liver Diseases | 08/22 | 12/22 | | |
NCT05100485: Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108) |
|
|
| Completed | N/A | 1000 | RoW | Esophagogasrtoduodendoscopy, Hepatic venous pressure gradient | Hepatopancreatobiliary Surgery Institute of Gansu Province, Tianjin Second People's Hospital, The Third People's Hospital of Taiyuan, Ehime University Graduate School of Medicine, Korea University Ansan Hospital, Hyogo Medical University, Zagazing University Faculty of Medicine, Institute of Liver and Biliary Sciences (ILBS), Changi General Hospital, Ruijin Hospital | Compensated Advanced Chronic Liver Disease | 01/23 | 01/23 | | |
NCT05551884: Non-invasive Diagnosis of Portal Hypertension in Cirrhosis Based on Metabolomics Technology |
|
|
| Recruiting | N/A | 500 | RoW | Metabolites and HVPG | Hepatopancreatobiliary Surgery Institute of Gansu Province, The Third People's Hospital of Taiyuan, Lishui Country People's Hospital, Shenyang Sixth People's Hospital, QuFu People's Hospital, Shulan (Hangzhou) Hospital | Cirrhosis, Liver, Portal Hypertension | 09/23 | 09/23 | | |
NCT06769893: A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging |
|
|
| Recruiting | N/A | 60 | RoW | 68Ga-NOTA-RCCB6 PET/CT Scan | Xijing Hospital | RCC, Renal Cell Cancer | 04/25 | 11/25 | | |
NCT05251272: A Combined Model Based on Spleen Stiffness, Liver Stiffness and Platelets for Assessing Portal Hypertension in Compensated Cirrhosis (CHESS2202) |
|
|
| Recruiting | N/A | 300 | RoW | Hepatic venous pressure gradient | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Shulan (Hangzhou) Hospital, The Third People's Hospital of Taiyuan, QuFu People's Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Portal Hypertension | 09/24 | 09/24 | | |
NCT06770478: A Study to Evaluate the Diagnostic Efficacy of 68Ga- MY6349 PET/CT in Patients With Tumours |
|
|
| Recruiting | N/A | 40 | RoW | 68Ga-MY6349 PET/CT Scan | Xijing Hospital | Tumour of Epithelial Origin, 68Ga-MY6349 | 07/27 | 07/27 | | |
NCT03982082: Ultrasound in Evaluating Muscle-Glycogen Content in Cancer Patients |
|
|
| Completed | N/A | 20 | US | Physical Therapy, Physiatric Procedure, Physical Medicine Procedure, Physical Therapeutics, Physical Therapy Procedure, Physiotherapy, Physiotherapy Procedure, PT, Questionnaire Administration, Ultrasound | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Cachexia, Malignant Solid Neoplasm | 01/24 | 01/25 | | |
NCT05140837: Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106) |
|
|
| Recruiting | N/A | 10000 | RoW | Psychometric hepatic encephalopathy score & Stroop test, Drug therapy | Hepatopancreatobiliary Surgery Institute of Gansu Province, The First Affiliated Hospital of Anhui Medical University, Beijing Ditan Hospital, Chongqing Public Health Medical Treatment Center, Meng Chao Hepatobiliary Hospital of Fujian Medical University, Guangxi Zhuang Autonomous Region People's Hospital, Shenzhen Third People's Hospital, Guizhou people's Hospital, Wuhan Union Hospital, China, Xiangya Hospital of Central South University, The Second Affiliated Hospital of Hainan Medical University, The Third Affiliated Hospital of Hebei Medical University, The Second Affiliated Hospital of Harbin Medical University, Henan Provincial People's Hospital, Ganzhou Fifth People's Hospital, The First Hospital of Jilin University, Jiangsu People's Hospital, First Hospital of China Medical University, The Second Affiliated Hospital of Baotou Medical College, Ningxia Medical University General Hospital, The Fourth People's Hospital of Qinghai Province, Xi'an High-tech Hospital, The 10th People's Hospital affiliated to Tongji University, Qilu Hospital of Shandong University, The Third People's Hospital of Taiyuan, Xichang People's Hospital, Tianjin Third Central Hospital, The Third People's Hospital of Tibet Autonomous Region, Xinjiang Autonomous Region People's Hospital, Second People's Hospital of Yunnan Province, Hangzhou Xixi hospital, LanZhou University | Hepatic Encephalopathy, Cirrhosis | 12/24 | 12/24 | | |
NCT05052892: A Novel Spleen-dedicated Stiffness Measured by FibroScan to Evaluate Cirrhotic Portal Hypertension (CHESS2105) |
|
|
| Not yet recruiting | N/A | 1000 | RoW | Hepatic venous pressure gradient | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Shulan (Hangzhou) Hospital, The Third People's Hospital of Taiyuan | Portal Hypertension | 09/25 | 09/25 | | |
NCT05965388: Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy |
|
|
| Not yet recruiting | N/A | 5000 | RoW | nucleoside analogues or interferon | Wen-hong Zhang, Shandong Provincial Hospital Affiliated to Shandong First Medical University, First Affiliated Hospital Xi'an Jiaotong University, The Affiliated Hospital of Xuzhou Medical University, First Affiliated Hospital of Fujian Medical University, The Third People's Hospital of Taiyuan, The First People's Hospital of Yunnan, The First Affiliated Hospital of Anhui Medical University, Wuhan Union Hospital, China, The First Affiliated Hospital with Nanjing Medical University | HBV, HCC | 02/29 | 02/29 | | |
| Kim, Tae Won |
NEMO, NCT03128021: Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response |
|
|
| Completed | 4 | 57 | US | Escitalopram Pill, Lexapro, Placebo, Levomilnacipran Pill, Fetzima | Howard Aizenstein, Weill Cornell Institute of Geriatric Psychiatry, National Institute of Mental Health (NIMH) | Major Depressive Disorder | 06/23 | 08/23 | | |
| Recruiting | 4 | 3944 | RoW | aspirin, clopidogrel, prasugrel, ticagrelor | Asan Medical Center | Coronary Artery Disease | 08/27 | 12/28 | | |
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) |
|
|
| Recruiting | 3 | 510 | Europe, Canada, Japan, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 10/26 | 02/27 | | |
NCT06545526: Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis |
|
|
| Recruiting | 3 | 28 | RoW | celecoxib monotherapy, celecoxib and metformin combination | Yonsei University | Familial Adenomatous Polyposis | 06/26 | 06/26 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 2 | 72 | RoW | Niclosamide, placebo | Yonsei University | Familial Adenomatous Polyposis | 12/22 | 02/23 | | |
NCT03435107: Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 33 | RoW | Durvalumab | Asan Medical Center | Metastatic Colorectal Cancer | 04/23 | 04/23 | | |
| Recruiting | 2 | 45 | RoW | Aatezolizumab plus Bevacizumab, Ticentriq plus Avastin | Tae Won Kim | Hepatocellular Carcinoma | 06/26 | 12/26 | | |
SPECTRUM, NCT05253118: Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS) |
|
|
| Recruiting | 2 | 28 | RoW | Tislelizumab, BGB-A317, Pemetrexed | Seoul National University Hospital, Gyeongsang National University Hospital, Kyunghee University Medical Center, Inje University Haeundae Paik Hospital, Chungnam National University Hospital | DLBCL | 12/25 | 02/26 | | |
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 140 | Europe, Japan, US, RoW | Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo | Eli Lilly and Company | Ulcerative Colitis, Ulcerative Colitis Chronic | 12/27 | 09/28 | | |
| Recruiting | 2 | 180 | Europe, Japan, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid® | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/26 | 07/27 | | |
| Recruiting | 2 | 250 | Europe, Canada, US, RoW | Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R) | Fore Biotherapeutics, Fore Biotherapeutics | Cancer Harboring BRAF Alterations | 06/25 | 08/26 | | |
ACE, NCT05741060: Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers |
|
|
| Active, not recruiting | 2 | 372 | US | S-equol, Equelle, Placebo | Akira Sekikawa, National Institute on Aging (NIA) | Arterial Stiffness, White Matter Lesions, Cognitive Decline | 10/26 | 01/27 | | |
| Active, not recruiting | 2 | 154 | Europe, Canada, Japan, US, RoW | Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A | GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd | Neoplasms, Rectal | 11/26 | 10/29 | | |
NCT04696848: The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors |
|
|
| Terminated | 1/2 | 25 | RoW | CKD-516 plus Durvalumab, CKD-516 plus MEDI4736 | Tae Won Kim | Colorectal Cancer, Solid Tumor | 03/23 | 03/23 | | |
| Active, not recruiting | 1/2 | 323 | US, RoW | FLX475, pembrolizumab (KEYTRUDA®) | RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC | Advanced Cancer | 09/24 | 01/25 | | |
NCT04903873: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 110 | US, RoW | EU101 | Eutilex | Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer | 09/25 | 12/25 | | |
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination |
|
|
| Recruiting | 1/2 | 576 | Europe, US, RoW | MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy | Merus N.V. | Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 03/26 | 03/27 | | |
NCT05394831: A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC |
|
|
| Recruiting | 1/2 | 150 | US, RoW | JIN-A02 | J Ints Bio | EGFR Mutant Advanced Non-small Cell Lung Cancer | 07/24 | 11/25 | | |
| Recruiting | 1 | 180 | Europe, US, RoW | IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan | IDEAYA Biosciences | Solid Tumor | 12/26 | 03/27 | | |
NCT03284502: HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 148 | RoW | HM95573, cobimetinib, HM95573, cetuximab | Hanmi Pharmaceutical Company Limited | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 09/24 | 12/24 | | |
NCT05159440: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer |
|
|
| Active, not recruiting | 1 | 70 | US, RoW | TORL-2-307-MAB | TORL Biotherapeutics, LLC, Translational Research in Oncology | Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma | 12/24 | 12/25 | | |
NCT05156866: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer |
|
|
| Recruiting | 1 | 70 | US, RoW | TORL-2-307-ADC | TORL Biotherapeutics, LLC, Translational Research in Oncology | Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma | 01/25 | 01/26 | | |
| Recruiting | 1 | 198 | Europe, US, RoW | ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1 | Enliven Therapeutics | HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification | 07/26 | 07/26 | | |
| Not yet recruiting | N/A | 103 | RoW | Daclatasvir and Asunaprevir, Daclatasvir and Asunaprevir combined treatment for 24 weeks | Sang Gyune Kim, Seoul National University Boramae Hospital, Severance Hospital, Inha University Hospital, Korea University, Gachon University Gil Medical Center, Hanyang University Seoul Hospital, Ewha Womans University Mokdong Hospital, Bristol-Myers Squibb | Chronic Hepatitis C | 12/18 | 12/22 | | |
| Recruiting | N/A | 180 | RoW | Online real-time quality measurement and feedback video-based CPR training, Online real-time feedback video-based CPR training without quality measurement, Conventional CPR training | Seoul National University Hospital | Cardiopulmonary Resuscitation, Education | 12/21 | 03/22 | | |
NCT04239794: The Influence of Type of Anesthesia on Postoperative Pain |
|
|
| Active, not recruiting | N/A | 468 | RoW | Propofol, Propofol 2%, Sevoflurane, Sevoflurane inhalant product | Seoul National University Hospital | Colo-rectal Cancer, Anesthesia | 12/23 | 01/24 | | |
NCT04203849: Prospective Cohort Study of Breast Cancer Patients Treated With Radiotherapy |
|
|
| Enrolling by invitation | N/A | 5000 | RoW | | National Cancer Center, Korea | Breast Cancer | 06/22 | 06/34 | | |
NCT05100485: Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108) |
|
|
| Completed | N/A | 1000 | RoW | Esophagogasrtoduodendoscopy, Hepatic venous pressure gradient | Hepatopancreatobiliary Surgery Institute of Gansu Province, Tianjin Second People's Hospital, The Third People's Hospital of Taiyuan, Ehime University Graduate School of Medicine, Korea University Ansan Hospital, Hyogo Medical University, Zagazing University Faculty of Medicine, Institute of Liver and Biliary Sciences (ILBS), Changi General Hospital, Ruijin Hospital | Compensated Advanced Chronic Liver Disease | 01/23 | 01/23 | | |
NCT05559502: High Flow Nasal Oxygenation vs Endotracheal Intubation on Recovery Profiles in Laryngeal Microsurgery |
|
|
| Recruiting | N/A | 52 | RoW | HFNO group, Optiflow, ET group, Portex, Smiths Medical International Ltd., South East England, United Kingdom | Ajou University School of Medicine | Cough | 06/24 | 06/24 | | |
NCT03969823: Whole Genomic Landscape of Advanced EGFR-mutant NSCLC |
|
|
| Active, not recruiting | N/A | 148 | RoW | Tagrisso, Osimertinib | Seoul National University Hospital, Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center | Locally Advanced or Metastatic NSCLC | 09/25 | 12/25 | | |
NCT06205212: High-flow Nasal Oxygenation During Preoxygenation and Atelectasis |
|
|
| Recruiting | N/A | 92 | RoW | high-flow nasal oxygen, facemask | Seoul National University Hospital, SMG-SNU Boramae Medical Center | Anesthesia, General, Pulmonary Atelectasis | 10/24 | 10/24 | | |
ICARUS, NCT05805280: IntravasCular Imaging-Guided Versus AngiogRaphy-GUided Drug-Eluting Stent Implantation for Fermoropopliteal Artery Disease |
|
|
| Recruiting | N/A | 100 | RoW | intravascular ultrasound-guided group, angiography-guided group | Asan Medical Center | Femoropopliteal Disease | 12/24 | 12/25 | | |
| Recruiting | N/A | 511 | RoW | | Asan Medical Center | Diabetes Mellitus | 12/25 | 12/25 | | |
NCT06216912: Gastric Volume in Paralyzed Obese Patients After High-flow Nasal Oxygen Therapy |
|
|
| Recruiting | N/A | 60 | RoW | | Seoul National University Hospital, SMG-SNU Boramae Medical Center | Undefined | 01/25 | 01/25 | | |
OBE-KMT22-01, NCT06250608: Evaluation of rSO2 Between Frontal Lesion Area and Normal Area of Brain by NIRSITX Using NIRS in Acute Ischemic Stroke Patients. |
|
|
| Recruiting | N/A | 35 | RoW | Pulse oximeter, NIRSITX | OBELAB, Inc., Helptrial Inc. | Acute Ischemic Stroke Patients | 12/25 | 12/25 | | |
| Completed | N/A | 21 | RoW | | Asan Medical Center, LN Robotics | Percutaneous Coronary Intervention | 03/24 | 04/24 | | |
NCT06441175: Effectiveness of Cricoid Pressure During Videolaryngoscopy Versus Direct Laryngoscopy |
|
|
| Not yet recruiting | N/A | 140 | NA | Intubation device order | Seoul National University Hospital, SMG-SNU Boramae Medical Center | Cricoid Pressure | 07/25 | 07/26 | | |
NCT06076083: Multi-omics Database for Integrative Microbiome Analysis in a Cohort of Korean Patients With Ankylosing Spondylitis |
|
|
| Recruiting | N/A | 600 | RoW | | Tae-Hwan Kim, Kyunghee University Medical Center | Ankylosing Spondylitis | 12/25 | 12/27 | | |
| Active, not recruiting | N/A | 797 | RoW | Propofol, Sevoflurane | Seoul National University Hospital, Korean Society of Anesthesiologists, Bundang Seoul National University Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Seoul St. Mary's Hospital, Seoul National University Boramae Hospital | Cancer of Colon, Anesthesia | 05/28 | 05/28 | | |
ASSIST, NCT05529459: Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD |
|
|
| Recruiting | N/A | 2400 | RoW | Percutaneous Coronary Intervention | Seung-Whan Lee, M.D., Ph.D., Biotronik Korea Co., Ltd | Coronary Disease | 12/26 | 07/30 | | |
PROVE-DM, NCT05579626: Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus |
|
|
| Recruiting | N/A | 4000 | RoW | high-intensity statin arm, low-intensity statin plus ezetimibe | Seung-Whan Lee, M.D., Ph.D., Yuhan Corporation | Pre Diabetes, ASCVD | 12/27 | 12/27 | | |
NCT04466189: Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy |
|
|
| Enrolling by invitation | N/A | 120 | RoW | | National Cancer Center, Korea | Pancreas Cancer | 08/28 | 08/28 | | |
| Recruiting | N/A | 6000 | RoW | Treatment, Intervention | Asan Medical Center | Aorta Disease, Peripheral Artery Disease | 12/34 | 12/44 | | |
NCT05467930: CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2 |
|
|
| Recruiting | N/A | 1000 | US | Survey, Medical History Review, Sample Collection | Columbia University, Gilead Sciences | COVID-19, SARS CoV 2 Infection | 05/25 | 05/26 | | |
NCT04466124: Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy |
|
|
| Enrolling by invitation | N/A | 500 | RoW | Liver Cancer Patients Treated With Proton Beam Therapy | National Cancer Center, Korea | Liver Cancer | 08/28 | 08/28 | | |
NCT05213962: Local and Regional Radiotherapy for Nipple Sparing Mastectomy With Implant |
|
|
| Enrolling by invitation | N/A | 128 | RoW | | National Cancer Center, Korea | Breast Cancer | 12/28 | 12/28 | | |
| Sarin, Shiv K |
| Active, not recruiting | 3 | 871 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
| Active, not recruiting | 2 | 271 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease | 12/25 | 03/26 | | |
NCT05100485: Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108) |
|
|
| Completed | N/A | 1000 | RoW | Esophagogasrtoduodendoscopy, Hepatic venous pressure gradient | Hepatopancreatobiliary Surgery Institute of Gansu Province, Tianjin Second People's Hospital, The Third People's Hospital of Taiyuan, Ehime University Graduate School of Medicine, Korea University Ansan Hospital, Hyogo Medical University, Zagazing University Faculty of Medicine, Institute of Liver and Biliary Sciences (ILBS), Changi General Hospital, Ruijin Hospital | Compensated Advanced Chronic Liver Disease | 01/23 | 01/23 | | |
| Recruiting | N/A | 96 | RoW | Weight loss | Institute of Liver and Biliary Sciences, India | Liver Cirrhosis, Obesity | 11/23 | 11/23 | | |
| Recruiting | N/A | 60 | RoW | IHPD, Western Diet | Institute of Liver and Biliary Sciences, India | Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome | 01/24 | 01/24 | | |
NCT06676813: Effect of Alternate Day Fasting Over Standard Medical Management Alone to Reverse Non-alcoholic Steatohepatitis. |
|
|
| Recruiting | N/A | 72 | RoW | Alternate day fasting | Institute of Liver and Biliary Sciences, India | Non Alcoholic Steatohepatitis | 06/25 | 06/25 | | |
NCT04975477: CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102) |
|
|
| Not yet recruiting | N/A | 1000 | Japan, RoW | Esophagogasrtoduodendoscopy and liver stiffness, hepatic venous pressure gradient | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Institute of Liver and Biliary Sciences (ILBS), Zagazig University, Korea University, Ehime University Graduate School of Medicine, Hyogo College of Medicine, Tianjin Second People's Hospital, Ruijin Hospital | Compensated Advanced Chronic Liver Disease | 08/21 | 08/21 | | |
| Zhu, Haidong |
| Recruiting | 1 | 40 | US | Salt pills, Placebo pills | Augusta University | High Blood Pressure | 12/22 | 12/22 | | |
NCT04520906: To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer |
|
|
| Recruiting | N/A | 139 | RoW | microwave ablation | Suzhou Hengruihongyuan Medical Technology Co. LTD | Hepatocellular Carcinoma | 01/23 | 12/23 | | |
| Active, not recruiting | N/A | 188 | RoW | Camrelizumab, TACE, Apatinib | Zhongda Hospital | Hepatocellular Carcinoma | 08/24 | 01/26 | | |
| Teng, Gao-Jun |
NCT05073744: Nalbuphine Versus Morphine for Perioperative Tumor Ablation |
|
|
| Recruiting | 4 | 316 | RoW | Nalbuphine, Tumor ablation using nalbuphine, Morphine, Tumor ablation using morphine | Zhongda Hospital | Nalbuphine Allergy, Ablation, Safety | 08/23 | 08/23 | | |
NCT05912686: High-Dose Atorvastatin for Vascular Wall Protection in Thrombectomy Patients |
|
|
| Not yet recruiting | 4 | 162 | RoW | Atorvastatin 80mg, Atorvastatin 20mg | Zhongda Hospital | Mechanical Thrombectomy, Acute Ischemic Stroke | 12/25 | 07/26 | | |
NCT05472896: TACE With Dicycloplatin(TP21) in Unresectable HCC |
|
|
| Recruiting | 3 | 332 | RoW | cTACE, Dicycloplatin (TP21), Epirubicin | Gao-jun Teng | Hepatocellular Carcinoma | 06/24 | 06/24 | | |
NCT05344924: TACE Combined With Penpulimab and Anlotinib for Advanced HCC |
|
|
| Recruiting | 2/3 | 109 | RoW | TACE+penpulimab+anlotinib vs. penpulimab+anlotinib, The combination of penpulimab+anlotinib with or without TACE | Zhongda Hospital | Hepatocellular Carcinoma | 03/23 | 03/24 | | |
NCT05280444: Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma |
|
|
| Recruiting | 2/3 | 216 | RoW | Idarubicin Hydrochloride for Injection, Anbijian | Zhongda Hospital | Hepatocellular Carcinoma | 06/23 | 07/23 | | |
| Recruiting | 2 | 72 | RoW | Tislelizumab in combination with cTACE, BGB-A317 | Zhongda Hospital | Hepatocellular Carcinoma | 11/22 | 11/23 | | |
| Recruiting | 2 | 32 | RoW | HAIC combined with donafenib and sintilimab, HAIC-donafenib-sintilimab | Zhongda Hospital | Cholangiocarcinoma | 06/23 | 07/23 | | |
| Recruiting | 1/2 | 60 | RoW | Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres | Zhongda Hospital | Unresectable Colorectal Liver Metastases | 12/24 | 12/24 | | |
NCT05957640: Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | Yttrium-90 carbon microspheres SIRT | Zhongda Hospital | Unresectable Hepatocellular Carcinoma | 05/25 | 05/25 | | |
| Completed | N/A | 826 | RoW | TACE+ICIs, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 05/22 | 02/23 | | |
NCT04060797: Endovascular Denervation Improves Limb Ischemia in Patients With Peripheral Artery Disease |
|
|
| Completed | N/A | 38 | RoW | endovascular denervation, PTA | Zhongda Hospital | PAD | 09/21 | 09/21 | | |
| Recruiting | N/A | 30 | RoW | Endovascular Denervation | Zhongda Hospital | Type 2 Diabetes Mellitus | 09/22 | 12/22 | | |
NCT05703750: Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301) |
|
|
| Recruiting | N/A | 228 | RoW | TACE ± Systemic therapy | Zhongda Hospital | Hepatocellular Carcinoma, Portal Hypertension | 06/23 | 12/23 | | |
NCT05704192: CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302) |
|
|
| Recruiting | N/A | 373 | RoW | TACE ± Systemic therapy | Zhongda Hospital | Hepatocellular Carcinoma, Portal Hypertension | 06/23 | 12/23 | | |
| Recruiting | N/A | 474 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 08/23 | | |
NCT05631561: Endovascular Denervation for the Treatment of Type 2 Diabetes Mellitus |
|
|
| Active, not recruiting | N/A | 30 | RoW | Endovascular denervation System (Generator and Catheter ) | Shanghai Golden Leaf MedTec Co. Ltd | Type 2 Diabetes Mellitus (T2DM) | 04/24 | 02/25 | | |
CHANCE2202, NCT05332496: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC |
|
|
| Recruiting | N/A | 220 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 09/23 | | |
| Active, not recruiting | N/A | 188 | RoW | Camrelizumab, TACE, Apatinib | Zhongda Hospital | Hepatocellular Carcinoma | 08/24 | 01/26 | | |
NCT06195917: Robotic-assisted Percutaneous Transhepatic Puncture |
|
|
| Recruiting | N/A | 20 | RoW | Robotic-assisted Interventional Percutaneous transhepatic puncture | Zhongda Hospital | Liver Diseases | 04/24 | 05/24 | | |
CHANCE023, NCT06024252: Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study |
|
|
| Not yet recruiting | N/A | 200 | NA | TACE, Atezolizumab, Bevacizumab | Zhongda Hospital | HCC | 12/23 | 06/24 | | |
NCT06190665: DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC |
|
|
| Recruiting | N/A | 188 | RoW | DEB-TACE with visualable microspheres, DEB-TACE with PVA microspheres | Zhongda Hospital | Hepatocellular Carcinoma | 12/25 | 12/26 | | |
ST-Y90-CP01, NCT06447727: Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM |
|
|
| Recruiting | N/A | 30 | RoW | SIRT with Yttrium-90 Microspheres, FOLFIRI and Bevacizumab | Zhongda Hospital | Colorectal Cancer Metastatic | 11/25 | 11/25 | | |
NCT06607120: Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies |
|
|
| Recruiting | N/A | 950 | RoW | | Zhongda Hospital | Hepatocellular Carcinoma | 01/25 | 03/25 | | |
NCT06593964: TACE With Thermosensitive Nanogel Versus Embosphere for HCC |
|
|
| Recruiting | N/A | 188 | RoW | Thermosensitive Nanogel Embolic Agent | Zhongda Hospital | Unresectable Hepatocellular Carcinoma | 04/26 | 04/26 | | |
NCT05956860: Radial Access for Abdominopelvic Vascular Intervention |
|
|
| Recruiting | N/A | 1143 | RoW | abdominopelvic vascular intervention through the radial artery access | Zhongda Hospital, Terumo Medical Corporation | Vascular Access Device Complications | 12/24 | 12/25 | | |
EDPAD, NCT05345431: Endovascular Denervation for the Treatment of Patients With Peripheral Arterial Disease |
|
|
| Recruiting | N/A | 54 | RoW | endovascular denervation, PTA | Zhongda Hospital | PAD | 06/25 | 06/26 | | |
NCT06021015: Safety and Efficacy of Polyvinyl Alcohol Sodium Acrylate Embolization Microspheres for CRLM |
|
|
| Not yet recruiting | N/A | 72 | NA | Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）, Irinotecan and HepaSphere Microspheres | Zhongda Hospital | Colorectal Cancer Liver Metastasis | 06/25 | 12/25 | | |
CHANCEsub, NCT05278195: Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers |
|
|
| Recruiting | N/A | 300 | RoW | | Zhongda Hospital | Hepatocellular Carcinoma | 12/22 | 12/23 | | |
| Li, Ying |
STRATEGY, NCT05310968: Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction |
|
|
| Recruiting | 4 | 970 | RoW | Tirofiban hydrochloride sodium chloride injection, Tirofiban hydrochloride sodium chloride injection placebo, Aspirin | Beijing Tiantan Hospital, GrandPharma (China) Co., Ltd. | Branch Atheromatous Disease | 06/24 | 09/24 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Shuxuening Injection, Placebo | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 06/25 | 12/26 | | |
